Preclinical Development of Russian Cancer Vaccine Finished
Groundbreaking therapeutic cancer mRNA-based vaccine is ready for clinical trials after the conclusion of preclinical development, which included animal testing, as Andrey Kaprin, the chief oncologist of the Ministry of Health, reports.
One of the vaccine’s unique features is that it will be developed individually for each patient. The process will include tumour sampling and conducting an in-depth analysis of the material. For this purpose, AI technologies will be used.
The vaccine is expected to "teach" the immune system to distinguish between healthy and pathological cells and only attack the latter.
The leading research and medical institutions of Russia are involved in the development of the vaccine, including the National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, the Gamaleya Research Institute of Epidemiology and Microbiology, and the Blokhin National Medical Oncology Research Center. Pyotr Chumakov, a virologist, corresponding member of the Russian Academy of Sciences, and the director of the Engelhardt Institute of Molecular Biology, has also made a significant contribution to the research.
After the official approval of the Ministry of Health, the researchers will proceed with the Phase I of clinical trials. The first human trials are expected to be carried out in autumn, 2025.
Source: PharmMedProm
Groundbreaking therapeutic cancer mRNA-based vaccine is ready for clinical trials after the conclusion of preclinical development, which included animal testing, as Andrey Kaprin, the chief oncologist of the Ministry of Health, reports.
One of the vaccine’s unique features is that it will be developed individually for each patient. The process will include tumour sampling and conducting an in-depth analysis of the material. For this purpose, AI technologies will be used.
The vaccine is expected to "teach" the immune system to distinguish between healthy and pathological cells and only attack the latter.
The leading research and medical institutions of Russia are involved in the development of the vaccine, including the National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, the Gamaleya Research Institute of Epidemiology and Microbiology, and the Blokhin National Medical Oncology Research Center. Pyotr Chumakov, a virologist, corresponding member of the Russian Academy of Sciences, and the director of the Engelhardt Institute of Molecular Biology, has also made a significant contribution to the research.
After the official approval of the Ministry of Health, the researchers will proceed with the Phase I of clinical trials. The first human trials are expected to be carried out in autumn, 2025.
Source: PharmMedProm